<DOC>
	<DOCNO>NCT00916578</DOCNO>
	<brief_summary>The goal clinical research study find XelodaÂ® ( capecitabine ) radiation therapy help control breast cancer respond well chemotherapy . The safety study treatment also study .</brief_summary>
	<brief_title>Xeloda ( Capecitabine ) External Beam Radiation</brief_title>
	<detailed_description>The Study Treatment : Radiation therapy capecitabine design interfere growth cancer cell . Study Therapy : If find eligible take part study , receive radiation therapy twice day , 5 day week , 5 -7 week . The schedule number week doctor 's decision base type breast cancer . The radiation treatment take 15-30 minute time . You take Capecitabine pill mouth every day 5-7 week receive radiation therapy . The pill take 2 time day , 12 hour apart , 30 minute eat food . On radiation therapy day , take capecitabine 2 hour radiation therapy . You give pill diary record time take dose capecitabine . Study Visits : Once week receive study treatment , physical exam . Length Study : You may remain study treatment 7 week . You take study treatment early disease get bad intolerable side effect occur . Based status cancer , become eligible surgery radiation , refer surgeon discus option . Follow-Up Visits : At Month 3 finish radiation therapy ( surgery , applicable ) , positron emission tomography / compute tomography ( PET/CT ) scan ultrasound check status disease . At Months 9 , 17 , 29 finishing radiation therapy surgery , may PET/CT scan , ultrasound , and/or routine blood test doctor think need . The amount blood drawn , , doctor 's decision base routine care . This investigational study . Capecitabine commercially available FDA approve treat breast cancer spread . Radiation therapy also commonly use treat breast cancer . The combination capecitabine radiation therapy commonly use treat rectal cancer . At time , consider investigational give combination capecitabine radiation therapy patient breast cancer . Up 60 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>1 . Histological confirmation invasive breast cancer 2 . No contraindication receive course radiation treatment ( pregnancy , prior radiation volume disease , systemic disease radiation therapy absolute contraindication ) 3 . Patients chemorefractory gross disease breast causing symptom ( pain , drainage , duress ) OR gross disease breast ( great equal T3 ) and/or lymph node ( ) progressive , persistent , minimally responsive chemotherapy deem inoperable questionable inoperable OR Recurrent gross disease previously unirradiated breast chest wall regional lymphatics ( core biopsy offer patient without gross disease breast ) . 4 . Are able swallow retain oral medication ( intact pill ) 5 . Age 18 6 . Female gender 1 . Have active uncontrolled infection 2 . Have dementia , alter mental status , psychiatric condition would prohibit understanding rendering informed consent 3 . Have use investigational drug within 21 day precede first dose study medication 4 . Are receive therapeutic anticoagulation therapy ( i.e . warfarin , heparin ) 5 . Uncontrolled arrhythmia CHF base clinical history physical exam 6 . Patient receive whole brain irradiation concurrently Xeloda treatment .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Advanced Inflammatory Breast Cancer</keyword>
	<keyword>Non-Inflammatory Breast Cancer</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Xeloda</keyword>
	<keyword>Concomitant Radiation</keyword>
	<keyword>Radiation Therapy</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>Women</keyword>
</DOC>